glp 1 and thyroid nodules Overscreening of patients on glucagon-like peptide-1 receptor agonists: A second “epidemic” of cancer overdiagnosis? GLP-1 RAs and Thyroid Cancer:

Especially in view of the frequent adverse effects leading to discontinuation, more knowledge on efficacy, safety, and tolerability is surely needed before their introduction in the clinical practice against T2D or obesity

Aaron Kesselheim, a professor of medicine at Harvard Medical School

Structured lifestyle interventions, including medical nutrition therapy or supervised weight loss programs

Crystal structure at 2.8 of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding

Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy

Leerinks Risinger chopped his 2030 sales forecast 38% from $21.6 billion based on the news, while a consensus of analysts cited by MarketWatch sliced its 2032 sales forecast for the drug from $20 billion to $15.5 billion